Inventor · disambiguated record
Tinghu Zhang
Also filed as: ZHANG TINGHU
49 granted patents·47 pending applications·190 citations·filing 2009–2025
97Inventor score
Files withDANA FARBER CANCER INST INC86ISOCURE BIOSCIENCES INC5SYROS PHARMACEUTICALS INC2UNIV LELAND STANFORD JUNIOR2LEE BENHUR1
Top patents by PatentIndex Score
96 records- 0197US11325910B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2020·Granted May 10, 2022·8 cites·24 claims
- 0297US10550121B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 4, 2020·15 cites·10 claims
- 0396US9382239B2Inhibitors of c-Jun-N-terminal kinase (JNK)DANA FARBER CANCER INST INC·Filed 2012·Granted Jul 5, 2016·30 cites·47 claims
- 0495US10144730B2Inhibitors of c-Jun-N-terminal kinase (JNK)DANA FARBER CANCER INST INC·Filed 2016·Granted Dec 4, 2018·16 cites·39 claims
- 0594US11932625B2Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Granted Mar 19, 2024·3 cites·30 claims
- 0694US10870651B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2015·Granted Dec 22, 2020·9 cites·36 claims
- 0794US10544138B2Tricyclic kinase inhibitors of MELK and methods of useDANA FARBER CANCER INST INC·Filed 2016·Granted Jan 28, 2020·12 cites·20 claims
- 0893US11040957B2Heteroaromatic compounds useful for the treatment of proliferative diseasesSYROS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·7 cites·21 claims
- 0993US10342798B2Fused bicyclic pyrimidine derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Jul 9, 2019·7 cites·42 claims
- 1092US11306070B2Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 19, 2022·8 cites·20 claims
- 1192US10787436B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Sep 29, 2020·5 cites·37 claims
- 1292US10695346B24,6-pyrimidinylene derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Jun 30, 2020·5 cites·32 claims
- 1392US10112927B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2013·Granted Oct 30, 2018·19 cites·20 claims
- 1491US10981903B2Inhibitors of c-Jun-N-terminal kinase (JNK)DANA FARBER CANCER INST INC·Filed 2018·Granted Apr 20, 2021·4 cites·32 claims
- 1591US10047070B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2014·Granted Aug 14, 2018·17 cites·19 claims
- 1690US12098154B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2022·Granted Sep 24, 2024·1 cites·37 claims
- 1787US11530219B2Ligands to cereblon (CRBN)DANA FARBER CANCER INST INC·Filed 2019·Granted Dec 20, 2022·3 cites·15 claims
- 1886US11142507B2Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2016·Granted Oct 12, 2021·7 cites·26 claims
- 1985US12168663B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2020·Granted Dec 17, 2024·1 cites·17 claims
- 2084US11807606B2Sulfonamide derivatives for protein degradationDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 7, 2023·4 cites·24 claims
- 2184US10906889B2Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2018·Granted Feb 2, 2021·4 cites·32 claims
- 2278US11505560B2Heterobifunctional compounds with improved specificityDANA FARBER CANCER INST INC·Filed 2018·Granted Nov 22, 2022·2 cites·16 claims
- 2378US10865204B2Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Dec 15, 2020·3 cites·30 claims
- 2474US12110292B2Ligands to cereblon (CRBN)DANA FARBER CANCER INST INC·Filed 2022·Granted Oct 8, 2024·0 cites·16 claims
- 2573US11858897B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2021·Granted Jan 2, 2024·0 cites·7 claims
- 2672US11827636B2Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Nov 28, 2023·0 cites·16 claims
- 2771US2022153730A9Inhibitors of c-jun-n-terminal kinase (jnk)DANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 2869US2024091213A1Compounds for tau protein degradationDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 2967US11066363B2Substituted 6,11-dihydro-5H-benzo[B]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2019·Granted Jul 20, 2021·0 cites·6 claims
- 3065US11247991B2Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 15, 2022·0 cites·23 claims
- 3164US12227488B2Small molecule degraders of Helios and methods of useDANA FARBER CANCER INST INC·Filed 2019·Granted Feb 18, 2025·0 cites·47 claims
- 3263US2022055998A1Inhibitors of cyclin-dependent kinasesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 3361US2023304024A1Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP)UNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 3461US2021315894A94,6-pyrimidinylene derivatives and uses thereofDANA FARBER CANCER INST INC·Filed 2020·Application pending·0 cites
- 3560US10508082B2Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPKDANA FARBER CANCER INST INC·Filed 2016·Granted Dec 17, 2019·0 cites·17 claims
- 3660US2016264551A1Heteroaromatic compounds useful for the treatment of prolferative diseasesSYROS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3760US2023339922A1Covalent egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 3860US2025221998A1Discovery of covalent egfr inhibitor through cysteine 775DANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 3959US2025388562A1Small molecule degraders of helios and methods of useDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 4058US2024336643A1Bifunctional compounds that degrade alk and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 4158US2021403460A1Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereofISOCURE BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4258US2025127909A1Compositions, Systems, and Methods for Modulating a Target GeneUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 4358US2023295137A1Covalent egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 4458US2021154184A1Compounds for tau protein degradationDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 4557US2024217970A1Phthalimido cereblon complex binders and transcription factor degraders and methods of useDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 4657US2024352021A1Covalent egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 4756US12281126B2Inhibitors of cyclin-dependent kinase 7 and uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Apr 22, 2025·0 cites·15 claims
- 4856US2024277852A1Inhibitors and degraders of pip4k proteinDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 4956US2024166665A1Covalent egfr inhibitors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 5055US11771697B2Small molecule degraders of polybromo-1 (PBRM1)DANA FARBER CANCER INST INC·Filed 2019·Granted Oct 3, 2023·0 cites·8 claims
Showing the top 50 of 96 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tinghu Zhang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →